Sanara Medtech Inc (SMTI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sanara Medtech Inc stock (SMTI) is currently trading at $16.34. Sanara Medtech Inc PS ratio (Price-to-Sales) is 1.61. Analyst consensus price target for SMTI is $36.00. WallStSmart rates SMTI as Sell.
- SMTI PE ratio analysis and historical PE chart
- SMTI PS ratio (Price-to-Sales) history and trend
- SMTI intrinsic value — DCF, Graham Number, EPV models
- SMTI stock price prediction 2025 2026 2027 2028 2029 2030
- SMTI fair value vs current price
- SMTI insider transactions and insider buying
- Is SMTI undervalued or overvalued?
- Sanara Medtech Inc financial analysis — revenue, earnings, cash flow
- SMTI Piotroski F-Score and Altman Z-Score
- SMTI analyst price target and Smart Rating
Sanara Medtech Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sanara Medtech Inc (SMTI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Sanara Medtech Inc (SMTI) Key Strengths (2)
Paying $1.61 for every $1 of annual revenue
Strong revenue growth at 21.50% annually
Supporting Valuation Data
Sanara Medtech Inc (SMTI) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 26.7x book value
Micro-cap company with very limited liquidity and high volatility
Thin operating margins with cost pressures present
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Sanara Medtech Inc (SMTI) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (1.61) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 21.50%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Book. Some valuation metrics including Price/Book (26.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -27.80%, Operating Margin at 11.20%, Profit Margin at -36.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -27.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SMTI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SMTI's Price-to-Sales ratio of 1.61x trades at a deep discount to its historical average of 4.88x (47th percentile). The current valuation is 94% below its historical high of 28.61x set in Dec 2020, and 3118% above its historical low of 0.05x in Dec 2018. Over the past 12 months, the PS ratio has compressed from ~3.1x as trailing revenue scaled faster than the stock price.
Compare SMTI with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Sanara Medtech Inc (SMTI) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Sanara Medtech Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 102M with 22% growth year-over-year. The company is currently unprofitable, posting a -36.8% profit margin.
Key Findings
Generating 1M in free cash flow and 2M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -36.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Sanara Medtech Inc maintain 22%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Sanara Medtech Inc.
Bottom Line
Sanara Medtech Inc offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sanara Medtech Inc(SMTI)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.